Our findings on the impact of PARP on prognosis suggest that targeting PARP alone would mostly benefit OSCC, GAC and PAAD patients, especially if stratified by PARP and/or HR status (gene alterations or expression). Here, PARP1 is linked to pancreatic adenocarcinoma.